Pfizer Comprehensive Income 2012-2026 | PFE

Pfizer comprehensive income from 2012 to 2026. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Pfizer comprehensive income for the quarter ending March 31, 2026 was $-8.066B, a 1.19% increase year-over-year.
  • Pfizer comprehensive income for 2024 was $-7.842B, a 1.49% decline from 2023.
  • Pfizer comprehensive income for 2023 was $-7.961B, a 4.13% decline from 2022.
  • Pfizer comprehensive income for 2022 was $-8.304B, a 40.82% increase from 2021.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Pfizer Annual Comprehensive Income
(Millions of US $)
2024 $-7,842
2023 $-7,961
2022 $-8,304
2021 $-5,897
2020 $-5,310
2019 $-11,640
2018 $-11,275
2017 $-9,321
2016 $-11,036
2015 $-9,522
2014 $-7,316
2013 $-3,271
2012 $-5,953
2011 $-4,129
Pfizer Quarterly Comprehensive Income
(Millions of US $)
2025-09-30 $-8,066
2025-06-30 $-8,438
2025-03-31 $-8,581
2024-12-31 $-7,842
2024-09-30 $-7,971
2024-06-30 $-7,816
2024-03-31 $-7,758
2023-12-31 $-7,961
2023-09-30 $-7,966
2023-06-30 $-8,102
2023-03-31 $-8,289
2022-12-31 $-8,304
2022-09-30 $-8,225
2022-06-30 $-7,119
2022-03-31 $-6,157
2021-12-31 $-5,897
2021-09-30 $-5,649
2021-06-30 $-4,758
2021-03-31 $-4,664
2020-12-31 $-5,310
2020-09-30 $-12,676
2020-06-30 $-13,246
2020-03-31 $-13,131
2019-12-31 $-11,640
2019-09-30 $-11,801
2019-06-30 $-11,535
2019-03-31 $-10,923
2018-12-31 $-11,275
2018-09-30 $-10,417
2018-06-30 $-10,003
2018-03-31 $-9,402
2017-12-31 $-9,321
2017-09-30 $-9,164
2017-06-30 $-10,181
2017-03-31 $-10,594
2016-12-31 $-11,036
2016-09-30 $-8,214
2016-06-30 $-8,891
2016-03-31 $-9,520
2015-12-31 $-9,522
2015-09-30 $-9,170
2015-06-30 $-8,521
2015-03-31 $-8,557
2014-12-31 $-7,316
2014-09-30 $-3,467
2014-06-30 $-3,152
2014-03-31 $-3,390
2013-12-31 $-3,271
2013-09-30 $-6,383
2013-06-30 $-6,465
2013-03-31 $-6,155
2012-12-31 $-5,953
2012-09-30 $-5,653
2012-06-30 $-6,008
2012-03-31 $-3,622
2011-12-31 $-4,129
2011-09-30 $-1,211
2011-06-30 $-952
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $153.074B $62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88